JG
AXSM icon

Jefferies Group’s Axsome Therapeutics AXSM Stock Holding History

Jefferies Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-37,500
Closed -$1.55M – 1551
2022
Q1 		$1.55M Buy
+37,500
New +$1.16M 0.01% 764
2019
Q2 		– Sell
-119,700
Closed -$1.7M – 2514
2019
Q1 		$1.7M Buy
+119,700
New +$1.11M 0.01% 995

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Jefferies Group's AXSM Position: Q2 2022 in Review

Jefferies Group sold out of Axsome Therapeutics (AXSM) in Q2 2022, closing a stake of 8,350 shares — an estimated $346K sold.

Jefferies Group first reported a position in AXSM in Q1 2019 and held it in 3 quarters. The position peaked at $965K in Q1 2019. 174 funds tracked by Wall St. Rank hold AXSM as of Q2 2022.

  • Jefferies Group reported no remaining Axsome Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Jefferies Group sold 8,350 Axsome Therapeutics shares in Q2 2022, an estimated $346K.
  • Jefferies Group first reported a position in Axsome Therapeutics in Q1 2019 and held it in 3 quarters.
  • Jefferies Group's Axsome Therapeutics position peaked at $965K in Q1 2019.
  • 174 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2022.

Based on Jefferies Group's 13F filing for Q2 2022, filed 15 Aug 2022.